Document is current

Any future updates will be listed below

Discontinuation of the development of remimazolam for ICU sedation in Japan: background and rationale

Crossref DOI link: https://doi.org/10.1186/s40560-026-00849-8

Published Online: 2026-01-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark